Latest News

External Peer Review of the Draft Public Health Goal for Perchlorate in Drinking Water
OEHHA posted the external peer review comments on the draft Public Health Goal for perchlorate in drinking water.
Nov 10, 2011, Program: Water
Request for Relevant Information on the Carcinogenic Hazards of C.I. Disperse Yellow 3, Dibenzanthracenes and dibenz[a,c]anthracene
OEHHA has selected the chemicals below for the CIC’s review for possible listing under Proposition 65. OEHHA is initiating the development of hazard identification materials on C.I. Disperse Yellow 3, Dibenzanthracenes and dibenz[a,c]anthracene.
Nov 10, 2011, Program: Proposition 65
Extension of Comment Period - Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil
On September 23, 2011, OEHHA published a notice in the California Regulatory Notice Register (Register 2011, No. 38-Z) proposing to establish a specific regulatory level posing no significant risk for Imazalil by amending Title 27, California Code of Regulations, section 25705.
Nov 7, 2011, Program: Proposition 65
Notice of Public Comment/Workshops for the Draft Technical Support Document for Exposure Assessment and Stochastic Analysis Nov 2011
OEHHA released for public comment the Air Toxics "Hot Spots" Program Risk Assessment Guidelines: Technical Support Document for Exposure Assessment and Stochastic Analysis.
Nov 7, 2011, Program: Air
Estrogen–progestogen (combined) used as menopausal therapy, Etoposide, Etoposide in combination with cisplatin and bleomycin, Methyl isobutyl ketone, MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture) Listed as Carcinogens
Estrogen–progestogen (combined) used as menopausal therapy, etoposide, etoposide in combination with cisplatin and bleomycin, methyl isobutyl ketone, MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture) listed as known to cause cancer under Proposition 65.
Nov 4, 2011, Program: Proposition 65
Meeting Synopsis and Slide Presentations Carcinogen Identification Committee Meeting Held on October 12, 2011
Meeting Synopsis and Slide Presentations Carcinogen Identification Committee Meeting Held on October 12, 2011
Nov 2, 2011, Program: Proposition 65
Extension of Comment Period - Proposed Amendment To Section 25707(B), Route of Exposure: Hexavalent Chromium (VI)
Extension of public comment period regarding the removal of the reference to hexavalent chromium in Section 25707(b)(4) as posing no significant risk when ingested. 
Oct 31, 2011, Program: Proposition 65
tris(1,3-dichloro-2-propyl) phosphate (TDCPP) Listed Effective October 28, 2011 as Known to the State to Cause Cancer
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) was listed effective 10/28/2011 as known to the State to cause cancer.
Oct 28, 2011, Program: Proposition 65
Hearing - Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil
Extension of comment period regarding the establishment of a specific regulatory level posing no significant risk for Imazalil.
Oct 27, 2011, Program: Proposition 65
Notice of Adoption to Text of Regulations Title 27, California Code of Regulations Amendment to Section 25805 Maximum Allowable Dose Level (MADL) for Avermectin B1
Notice of adoption to text of regulations Title 27, California Code of Regulations amendment to section 25805 Maximum Allowable Dose Level (MADL) for Avermectin B1
Oct 26, 2011, Program: Proposition 65

Pages